MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 465463 | Name: Dovitinib-RIBOTAC
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dovitinib-RIBOTAC is a ribonuclease targeting chimera, or RIBOTAC, that stops disease progression in mice engineered to have breast cancer.

Chemical Structure

Dovitinib-RIBOTAC
Dovitinib-RIBOTAC
CAS#2759351-68-1

Theoretical Analysis

MedKoo Cat#: 465463

Name: Dovitinib-RIBOTAC

CAS#: 2759351-68-1

Chemical Formula: C51H56FN9O10S

Exact Mass: 1005.3855

Molecular Weight: 1006.12

Elemental Analysis: C, 60.88; H, 5.61; F, 1.89; N, 12.53; O, 15.90; S, 3.19

Price and Availability

Size Price Availability Quantity
1mg USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Dovitinib-RIBOTAC; DovitinibRIBOTAC; Dovitinib RIBOTAC;
IUPAC/Chemical Name
ethyl (Z)-5-(4-((1-(4-(2-(4-amino-5-fluoro-2-oxo-1,2-dihydroquinolin-3-yl)-1H-benzo[d]imidazol-5-yl)piperazin-1-yl)-4-oxo-8,11,14-trioxa-3,5-diazahexadecan-16-yl)oxy)-3-hydroxybenzylidene)-4-oxo-2-(phenylamino)-4,5-dihydrothiophene-3-carboxylate
InChi Key
KUSYTHTUVIPDQL-CTYAKMLPSA-N
InChi Code
InChI=1S/C51H56FN9O10S/c1-2-70-50(65)44-46(63)41(72-49(44)56-33-7-4-3-5-8-33)30-32-11-14-40(39(62)29-32)71-28-27-69-26-25-68-24-23-67-22-16-55-51(66)54-15-17-60-18-20-61(21-19-60)34-12-13-36-38(31-34)58-47(57-36)43-45(53)42-35(52)9-6-10-37(42)59-48(43)64/h3-14,29-31,56,62H,2,15-28H2,1H3,(H,57,58)(H3,53,59,64)(H2,54,55,66)/b41-30-
SMILES Code
O=C(OCC)C1=C(S/C(C1=O)=C\C2=CC(O)=C(OCCOCCOCCOCCNC(NCCN3CCN(C4=CC=C(NC(C5=C(N)C6=C(C=CC=C6F)NC5=O)=N7)C7=C4)CC3)=O)C=C2)NC8=CC=CC=C8
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,006.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: García-Quiroz J, Cárdenas-Ochoa N, García-Becerra R, Morales-Guadarrama G, Méndez-Pérez EA, Santos-Cuevas C, Ramírez-Nava GJ, Segovia-Mendoza M, Prado- García H, Avila E, Larrea F, Díaz L. Antitumoral effects of dovitinib in triple- negative breast cancer are synergized by calcitriol in vivo and in vitro. J Steroid Biochem Mol Biol. 2021 Aug 24;214:105979. doi: 10.1016/j.jsbmb.2021.105979. Epub ahead of print. PMID: 34438041. 2: Zhang P, Liu X, Abegg D, Tanaka T, Tong Y, Benhamou RI, Baisden J, Crynen G, Meyer SM, Cameron MD, Chatterjee AK, Adibekian A, Childs-Disney JL, Disney MD. Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment. J Am Chem Soc. 2021 Aug 25;143(33):13044-13055. doi: 10.1021/jacs.1c02248. Epub 2021 Aug 13. PMID: 34387474. 3: Woei-A-Jin FJSH, Weijl NI, Burgmans MC, Fariña Sarasqueta A, van Wezel JT, Wasser MNJM, Coenraad MJ, Burggraaf J, Osanto S. Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study. Oncologist. 2021 Jul 12. doi: 10.1002/onco.13901. Epub ahead of print. PMID: 34251745. 4: He Y, Luo Y, Huang L, Zhang D, Wang X, Ji J, Liang S. New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Pharmacol Res. 2021 Aug;170:105732. doi: 10.1016/j.phrs.2021.105732. Epub 2021 Jun 15. PMID: 34139345. 5: Rajendran R, Böttiger G, Dentzien N, Rajendran V, Sharifi B, Ergün S, Stadelmann C, Karnati S, Berghoff M. Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes. Cells. 2021 May 25;10(6):1318. doi: 10.3390/cells10061318. PMID: 34070622; PMCID: PMC8228431. 6: Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta- analysis of randomized controlled trials. World J Gastroenterol. 2021 May 21;27(19):2415-2433. doi: 10.3748/wjg.v27.i19.2415. PMID: 34040331; PMCID: PMC8130040. 7: Kanegasaki S, Tsuchiya T. A possible way to prevent the progression of bone lesions in multiple myeloma via Src-homology-region-2-domain-containing- phosphatase-1 activation. J Cell Biochem. 2021 May 10. doi: 10.1002/jcb.29949. Epub ahead of print. PMID: 33969922. 8: Kardoust Parizi M, Margulis V, Lotan Y, Mori K, Shariat SF. Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. Urol Oncol. 2021 Jul;39(7):409-421. doi: 10.1016/j.urolonc.2021.01.025. Epub 2021 Feb 26. PMID: 33642228. 9: Ko J, Meyer AN, Haas M, Donoghue DJ. Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment. Oncotarget. 2021 Jan 5;12(1):22-36. doi: 10.18632/oncotarget.27859. PMID: 33456711; PMCID: PMC7800776. 10: Kim J, Lee DH, Badamtsetseg B, Lee S, Kim SA. Anti-Proliferative Effect of Allium senescens L. Extract in Human T-Cell Acute Lymphocytic Leukemia Cells. Molecules. 2020 Dec 23;26(1):35. doi: 10.3390/molecules26010035. PMID: 33374788; PMCID: PMC7795430. 11: Carneiro ACDM, De Vito FB, Moraes-Souza H, Crema VO. RhoA/ROCKs signaling is increased by treatment with TKI-258 and leads to increased apoptosis in SCC-4 oral squamous cell carcinoma cell line. J Oral Pathol Med. 2021 Apr;50(4):394-402. doi: 10.1111/jop.13143. Epub 2020 Dec 7. PMID: 33222274. 12: Luo H, Zhang T, Cheng P, Li D, Ogorodniitchouk O, Lahmamssi C, Wang G, Lan M. Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors. Oncol Lett. 2020 Sep;20(3):2525-2536. doi: 10.3892/ol.2020.11858. Epub 2020 Jul 10. PMID: 32782571; PMCID: PMC7400342. 13: Das A, Martinez Santos JL, Alshareef M, Porto GBF, Infinger LK, Vandergrift WA 3rd, Lindhorst SM, Varma AK, Patel SJ, Cachia D. In Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells. Cancer Invest. 2020 Jul;38(6):349-355. doi: 10.1080/07357907.2020.1773844. Epub 2020 Jun 8. PMID: 32441531. 14: Taylor MH, Alva AS, Larson T, Szpakowski S, Purkaystha D, Amin A, Karpiak L, Piha-Paul SA. A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. Oncotarget. 2020 Apr 7;11(14):1235-1243. doi: 10.18632/oncotarget.27530. PMID: 32292573; PMCID: PMC7147086. 15: AlRabiah H, Kadi AA, Aljohar HI, Attwa MW, Al-Shakliah NS, Attia SM, Mostafa GA. A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma. Drug Des Devel Ther. 2020 Jan 28;14:407-415. doi: 10.2147/DDDT.S223573. PMID: 32095071; PMCID: PMC6995292. 16: Silveira IC, Carneiro ACDM, Hiss LS, Crema VO. Anti-Proliferative Role of the Tyrosine Kinase Inhibitors TKI-258 on Oral Squamous Cell Carcinoma In Vitro. Anticancer Agents Med Chem. 2020;20(6):751-755. doi: 10.2174/1871520620666200213110944. PMID: 32053087. 17: Barnes EJ, Leonard J, Medeiros BC, Druker BJ, Tognon CE. Functional characterization of two rare BCR-FGFR1+ leukemias. Cold Spring Harb Mol Case Stud. 2020 Apr 1;6(2):a004838. doi: 10.1101/mcs.a004838. PMID: 31980503; PMCID: PMC7133745. 18: Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, Chen HZ, Reeser JW, Wing MR, Miya J, Samorodnitsky E, Smith AM, Dao T, Martin DM, Ciombor KK, Hays J, Freud AG, Roychowdhury S. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Mol Cancer Ther. 2020 Mar;19(3):847-857. doi: 10.1158/1535-7163.MCT-19-0631. Epub 2020 Jan 7. PMID: 31911531; PMCID: PMC7359896. 19: Roskoski R Jr. The role of fibroblast growth factor receptor (FGFR) protein- tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567. doi: 10.1016/j.phrs.2019.104567. Epub 2019 Nov 23. PMID: 31770593. 20: Comparison of the Effects of Dovitinib and Bevacizumab on Reducing Neovascularization in an Experimental Rat Corneal Neovascularization Model: Erratum. Cornea. 2020 Jan;39(1):e4. doi: 10.1097/ICO.0000000000002180. Erratum for: Cornea. 2019 Sep;38(9):1161-1168. PMID: 31688199.